The neoplastic population of chronic myeloid leukemia (CML) cells can produce transforming growth factor (TGF-β) in order to decrease the expression of HLA-class II molecules and in turn become less immunogenic [33,34,35]. Here, TGFB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.